Precision oncology: A new era of cancer clinical trials

Lindsay A. Renfro, Ming Wen An, Sumithra J. Mandrekar

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


Traditionally, site of disease and anatomic staging have been used to define patient populations to be studied in individual cancer clinical trials. In the past decade, however, oncology has become increasingly understood on a cellular and molecular level, with many cancer subtypes being described as a function of biomarkers or tumor genetic mutations. With these changes in the science of oncology have come changes to the way we design and perform clinical trials. Increasingly common are trials tailored to detect enhanced efficacy in a patient subpopulation, e.g. patients with a known biomarker value or whose tumors harbor a specific genetic mutation. Here, we provide an overview of traditional and newer biomarker-based trial designs, and highlight lessons learned through implementation of several ongoing and recently completed trials.

Original languageEnglish (US)
Pages (from-to)121-126
Number of pages6
JournalCancer Letters
StatePublished - Feb 28 2017


  • Adaptive design
  • Biomarker-based design
  • Clinical trial
  • Oncology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Precision oncology: A new era of cancer clinical trials'. Together they form a unique fingerprint.

Cite this